Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles G Drake

Showing results (31-40 of 266) with videos related to

Pageof 27
Sort By:
Current Opinion in Oncology|March 14, 2012
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyEmmanuel S Antonarakis, Charles G Drake
Current Urology Reports|April 29, 2010
Update: immunological strategies for prostate cancerCharles G Drake, Emmanuel S Antonarakis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2013
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapyChristopher J Nirschl, Charles G Drake
Cancer Metastasis Reviews|January 31, 2014
Immunotherapy for prostate cancer: recent developments and future challengesMichael T Schweizer, Charles G Drake
Current Opinion in Urology|February 25, 2010
Current status of immunological therapies for prostate cancerEmmanuel S Antonarakis, Charles G Drake
Nature Biomedical Engineering|April 25, 2019
Combined local and systemic attacksCatherine S Spina, Charles G Drake
Blood|September 24, 2005
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccinesGang Zhou, Charles G Drake, Hyam I Levitsky
European Urology|October 30, 2020
Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate CancerM Brent McHenry, Charles G Drake, Karim Fizazi
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 3, 2014
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directionsAbhishek Tripathi, Charles G Drake, Lauren C Harshman
Advances in Immunology|May 30, 2006
Mechanisms of immune evasion by tumorsCharles G Drake, Elizabeth Jaffee, Drew M Pardoll
Pageof 27

Showing results (31-40 of 266) with videos related to

Sort By:
Pageof 27
Current Opinion in Oncology|March 14, 2012
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyEmmanuel S Antonarakis, Charles G Drake
Current Urology Reports|April 29, 2010
Update: immunological strategies for prostate cancerCharles G Drake, Emmanuel S Antonarakis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2013
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapyChristopher J Nirschl, Charles G Drake
Cancer Metastasis Reviews|January 31, 2014
Immunotherapy for prostate cancer: recent developments and future challengesMichael T Schweizer, Charles G Drake
Current Opinion in Urology|February 25, 2010
Current status of immunological therapies for prostate cancerEmmanuel S Antonarakis, Charles G Drake
Nature Biomedical Engineering|April 25, 2019
Combined local and systemic attacksCatherine S Spina, Charles G Drake
Blood|September 24, 2005
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccinesGang Zhou, Charles G Drake, Hyam I Levitsky
European Urology|October 30, 2020
Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate CancerM Brent McHenry, Charles G Drake, Karim Fizazi
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 3, 2014
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directionsAbhishek Tripathi, Charles G Drake, Lauren C Harshman
Advances in Immunology|May 30, 2006
Mechanisms of immune evasion by tumorsCharles G Drake, Elizabeth Jaffee, Drew M Pardoll
Pageof 27